Scalable AAV production and purification by plasmid DNA transfection of HEK293 cells
- Detailed Technology Description
- Recombinant adeno-associated virus (rAAV) vectors have emerged as one of the most versatile and successful gene therapy delivery vectors. Good Manufacturing Practice (GMP) Production Facility at Nationwide Children's Hospital has developed a process to increase the scale of rAAV production using DNA plasmid based transfection of HEK293 cells. This process allows generation of AAV at a 10-fold larger scale than previously produced in the GMP facility thereby supporting trials that require higher doses of clinical grade vector.
- Countries
- Not Available
- Application No.
- None
- *Abstract
-
Recombinant adeno-associated virus (rAAV) vectors have emerged as one of the most versatile and successful gene therapy delivery vectors. Good Manufacturing Practice (GMP) Production Facility at Nationwide Children's Hospital has developed a process to increase the scale of rAAV production using DNA plasmid based transfection of HEK293 cells. This process allows generation of AAV at a 10-fold larger scale than previously produced in the GMP facility thereby supporting trials that require higher doses of clinical grade vector.
- *IP Issue Date
- None
- *IP Type
- Other Patent
- Country/Region
- USA
For more information, please click Here
